FBG - Strongbridge spikes after peer-review publication of late-stage study on hormonal disorder

Strongbridge Biopharma (SBBP) rose ~21.5% in early after hours in reaction to the company announcement of a peer-reviewed publication of its results from Phase 3 SONICS study of Recorlev (levoketoconazole) in patients with Cushing’s syndrome.The manuscript titled “Levoketoconazole in the Treatment of Patients with Cushing’s Syndrome and Diabetes Mellitus: Phase 3 SONICS Results,” included a sub-analysis of patients with diabetes mellitus receiving Recorlev as a potential treatment of endogenous Cushing’s syndrome.Published in the peer-reviewed journal, Frontiers in Endocrinology, results have indicated a significant cortisol control in the patients with a meaningful improvement in key glycemic measures, such as hemoglobin A1c (HbA1c) and fasting blood glucose (FBG), the company said.The results were first disclosed in the 2019 Annual Meeting of the Endocrine Society (“ENDO”), held March 23 – 26.

For further details see:

Strongbridge spikes after peer-review publication of late-stage study on hormonal disorder